- Home
- ELVN vs ATUS Comparison
ELVN vs ATUS Comparison
Compare ELVN & ATUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- ATUS
- Stock Information
- Founded
- ELVN 2016
- ATUS 2015
- Country
- ELVN United States
- ATUS United States
- Employees
- ELVN N/A
- ATUS N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- ATUS Cable & Other Pay Television Services
- Sector
- ELVN Health Care
- ATUS Telecommunications
- Exchange
- ELVN Nasdaq
- ATUS Nasdaq
- Market Cap
- ELVN 1.2B
- ATUS 1.0B
- IPO Year
- ELVN 2020
- ATUS 2017
- Fundamental
- Price
- ELVN $22.92
- ATUS $2.60
- Analyst Decision
- ELVN Strong Buy
- ATUS Buy
- Analyst Count
- ELVN 5
- ATUS 6
- Target Price
- ELVN $41.20
- ATUS $2.88
- AVG Volume (30 Days)
- ELVN 728.3K
- ATUS 6.2M
- Earning Date
- ELVN 08-12-2025
- ATUS 08-07-2025
- Dividend Yield
- ELVN N/A
- ATUS N/A
- EPS Growth
- ELVN N/A
- ATUS N/A
- EPS
- ELVN N/A
- ATUS N/A
- Revenue
- ELVN N/A
- ATUS $8,855,764,000.00
- Revenue This Year
- ELVN N/A
- ATUS N/A
- Revenue Next Year
- ELVN N/A
- ATUS N/A
- P/E Ratio
- ELVN N/A
- ATUS N/A
- Revenue Growth
- ELVN N/A
- ATUS N/A
- 52 Week Low
- ELVN $13.30
- ATUS $1.52
- 52 Week High
- ELVN $30.03
- ATUS $3.20
- Technical
- Relative Strength Index (RSI)
- ELVN 60.45
- ATUS 64.06
- Support Level
- ELVN $19.38
- ATUS $2.53
- Resistance Level
- ELVN $21.34
- ATUS $2.79
- Average True Range (ATR)
- ELVN 1.27
- ATUS 0.13
- MACD
- ELVN 0.11
- ATUS 0.07
- Stochastic Oscillator
- ELVN 88.47
- ATUS 74.61
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About ATUS Altice USA Inc.
Altice Europe acquired privately held US cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and business in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York.